| Literature DB >> 28337639 |
Marta Szandruk1, Anna Merwid-Ląd2, Adam Szeląg2.
Abstract
BACKGROUND: Inflammatory bowel disease (IBD) [including Crohn's disease (CD) and ulcerative colitis (UC)] constitutes an important clinical problem. The pathogenesis of IBD remains unclear. It is believed that immune dysfunction, inflammatory mediators and oxidative damage play crucial roles in development of IBD. The condition is clinically associated with symptoms ranging from mild to severe during relapses, depending on the affected segment of the gastrointestinal tract. Bloody diarrhea with mucus, abdominal pain, weight loss and anemia are initial symptoms of both CD and UC. Differences between diseases become more evident in time, along with the development of intestinal and extraintestinal complications. Mangiferin (1,3,6,7-tetrahydroxyxanthone-C-2-β-D-glucoside), a natural polyphenol in plants, exerts antioxidant and anti-inflammatory effects making it an interesting option for the treatment of inflammatory pathologies associated with oxidative stress in humans, such as IBD.Entities:
Keywords: Experimental colitis; Inflammatory bowel disease; Interleukin-17; Mangiferin; Trinitrobenzensulfonic acid; Tumor necrosis factor α
Mesh:
Substances:
Year: 2017 PMID: 28337639 PMCID: PMC5859701 DOI: 10.1007/s10787-017-0337-0
Source DB: PubMed Journal: Inflammopharmacology ISSN: 0925-4692 Impact factor: 4.473
Fig. 1Multiple reaction monitoring (MRM) chromatograms recorded during the analysis of the methanol extract of mangiferin standard (a) and obtained mangiferin (b). In the whole range of peak there is only one mass 421.1 m/z
Fig. 2The impact of mangiferin on rat: body weight (a), colon mass index (b), macroscopic damage of colon tissues (c), microscopic damage of colon tissues (d), colon tissues TNF-α concentration (e), colon tissues IL-17 concentration (f), colon tissues MDA concentration (g), SOD activity in colon tissues (h) in experimental groups; K—the control group, M10, M30, M100—groups receiving, respectively, 10, 30 or 100 mg/kg of mangiferin intragastrically, C—the group receiving only TNBS rectally, CM10, CM30, CM100—groups receiving 10, 30 or 100 mg/kg of mangiferin with TNBS, respectively. Macroscopic evaluation of colonic tissue damage according to the criteria described by Galvez et al.: score 0 (no damage); score 1 (hyperemia, no ulcers); score 2 (linear ulcer with no significant inflammation); score 3 (linear ulcer with inflammation at one site); score 4 (two or more sites of ulceration or inflammation and ulceration or inflammation extending <1 cm); score 5 (two or more major sites of ulceration or inflammation extending >1 cm along the length of the colon) Microscopic evaluation of colonic tissue damage: in mucosal epithelium and lamina propria: ulceration (0–4), mononuclear cell infiltration (0–3), polymorphonuclear cell infiltration (0–3); in submucosa: edema (0–3), mononuclear cell infiltration (0–3), polymorphonuclear cell infiltration (0–3); in muscular layer: mononuclear cell infiltration (0–3), polymorphonuclear cell infiltration (0–3). Scoring scale: 0—none, 1—mild, 2—moderate, 3—severe, 4—full-thickness; maximum score: 25. Results are presented as mean values ± SD. Differences ***p < 0.001 vs the control group; **p < 0.01 vs the control group; *p < 0.05 vs the control group; ### p < 0.001 vs the TNBS group; ## p < 0.01 vs the TNBS group; # p < 0.05 vs the TNBS group were deemed statistically significant
Fig. 3Microscopic appearance of colon tissues after hematoxylin-eosin staining showed that mangiferin reduces histological damage; control group (K), groups receiving mangiferin at the doses of 10 or 30 or 100 mg/kg (M10, M30, M100, respectively), group receiving only TNBS (C), groups receiving mangiferin at the doses of 10 or 30 or 100 mg/kg with TNBS (CM10, CM30, CM100, respectively); magnification 200×
Fig. 4Microscopic appearance of colon tissues after Giemsa staining showed that mangiferin reduces the inflammatory cells infiltration (a); and after Alcian blue staining showed that mangiferin prevents loss of mucus layer (b); control group (K), group receiving only TNBS (C), groups receiving mangiferin at the doses of 10 or 30 or 100 mg/kg with TNBS (CM10, CM30, CM100, respectively); magnification 200×